{
    "clinical_study": {
        "@rank": "141043", 
        "arm_group": {
            "arm_group_label": "5-ASA", 
            "description": "Patient's treated with oral 5-ASA"
        }, 
        "brief_summary": {
            "textblock": "The objectives of this study are to investigate how oral 5-ASA drugs have been used in the\n      condition without symptoms such as abdominal pain or diarrhea/bloody stool (remission\n      stage), or in the transition from the condition with symptoms such as abdominal pain or\n      diarrhea/bloody stool (active stage) to the remission stage in ulcerative colitis and to\n      study how many patients will be able to maintain the remission stage during the observation\n      period and how many times the patients will experience the active stage (relapse), as well\n      as how symptoms will change during the observation period to discover better treatment\n      plans."
        }, 
        "brief_title": "Observational Study in the Management of Ulcerative Colitis With Oral 5-ASA", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "Period: 2012-2014 Observation Time: 0, 26week, 52week\n\n      Matters investigated:\n\n        1. pUCDAI scores(Stool frequency, Bloody stool, Physician's global assessment)\n\n        2. Medication adherence (VAS scale)\n\n        3. Remission, Relapse\n\n        4. Age, gender, body height, body weight, date of diagnosis, extension of inflammation,\n           classification by clinical course, smoking, alcohol, work, disease complication,\n           duration of remission maintained to enrollment(remission patient)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Outpatients\n\n          2. Adult patients who have been diagnosed with mild to moderate active ulcerative\n             colitis or ulcerative colitis in the remission stage according to the diagnostic\n             criteria for ulcerative colitis (draft revised on February 13, 2010)\n\n          3. Patients who have been treated with remission induction therapy or remission\n             maintenance therapy with oral 5-ASA drugs (Pentasa\u00ae tablets 250 mg, Pentasa\u00ae tablets\n             500 mg, Asacol\u00ae tablets 400 mg and Salazopyrin\u00ae tablets 500 mg as well as drugs that\n             have been proved equivalent to these drugs)\n\n          4. Patients who have received adequate information regarding this study and understood\n             thoroughly, and then voluntarily submitted written consent forms upon participation\n             in this study\n\n        Exclusion Criteria:\n\n          1. Patients with severe active ulcerative / fulminant ulcerative colitis according to\n             the diagnostic criteria for ulcerative colitis (draft revised on February 13, 2012)\n\n          2. Patients who have received total / subtotal colectomy\n\n          3. Patients who have been complicated with malignant tumor\n\n          4. Patients who are pregnant or possibly pregnant\n\n          5. Other patients whom investigators and subinvestigators considered inappropriate to\n             participate in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "University, Main hospital, General Hospital, General Practitioner"
            }
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654783", 
            "org_study_id": "OPTIMUM-2012"
        }, 
        "intervention_browse": {
            "mesh_term": "Mesalamine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "5-ASA, ulcerative colitis, active, remission, adherence", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bunkyo-ku", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "113-8519"
                }, 
                "name": "Tokyo Medical and Dental University"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Study on Clinical Practice in the Management of Ulcerative Colitis With Oral 5-Aminosalicylic Acid in Japan", 
        "overall_official": {
            "affiliation": "Kyorin Pharmaceutical Co.,Ltd", 
            "last_name": "Soji Omuro, Mr.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Cumulative non-relapse rate", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654783"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of relapses", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "The pUCDAI scores and the scores that constitute these pUCDAI scores at each assessment period", 
                "safety_issue": "No", 
                "time_frame": "0, 26 weeks, 52 weeks"
            }, 
            {
                "measure": "Medication adherence:Measured by patient response to visual analog scale", 
                "safety_issue": "No", 
                "time_frame": "0, 26 weeks, 52 weeks"
            }
        ], 
        "source": "Kyorin Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyorin Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}